MA51073B1 - Inhibition de l'idh-1 mutante - Google Patents

Inhibition de l'idh-1 mutante

Info

Publication number
MA51073B1
MA51073B1 MA51073A MA51073A MA51073B1 MA 51073 B1 MA51073 B1 MA 51073B1 MA 51073 A MA51073 A MA 51073A MA 51073 A MA51073 A MA 51073A MA 51073 B1 MA51073 B1 MA 51073B1
Authority
MA
Morocco
Prior art keywords
inhibition
mutant idh
idh
azacitidine
aza
Prior art date
Application number
MA51073A
Other languages
English (en)
Other versions
MA51073A (fr
Inventor
Susan Ashwell
Patrick F Kelly
Alan Collis
Jeff Davis
Duncan Walker
Blythe Thomson
Lu Wei
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Priority claimed from PCT/US2019/032747 external-priority patent/WO2019222553A1/fr
Publication of MA51073A publication Critical patent/MA51073A/fr
Publication of MA51073B1 publication Critical patent/MA51073B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés de traitement de patients chez lesquels on a diagnostiqué un cancer présentant une mutation idh-1, comprenant l'administration thérapeutique d'un certain inhibiteur d'idh-1 mutante en tant qu'agent unique, ou en combinaison avec de l'azacitidine (aza).
MA51073A 2018-05-16 2019-05-16 Inhibition de l'idh-1 mutante MA51073B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862672461P 2018-05-16 2018-05-16
PCT/US2019/032747 WO2019222553A1 (fr) 2018-05-16 2019-05-16 Inhibition de l'idh-1 mutante

Publications (2)

Publication Number Publication Date
MA51073A MA51073A (fr) 2020-10-14
MA51073B1 true MA51073B1 (fr) 2023-04-28

Family

ID=86227080

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51073A MA51073B1 (fr) 2018-05-16 2019-05-16 Inhibition de l'idh-1 mutante

Country Status (1)

Country Link
MA (1) MA51073B1 (fr)

Also Published As

Publication number Publication date
MA51073A (fr) 2020-10-14

Similar Documents

Publication Publication Date Title
MA47399A (fr) Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MX2021005011A (es) Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7).
MA43000B1 (fr) Polythérapie pour le traitement de tumeurs malignes
MA47107B1 (fr) Dérivés de benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine et pyrido[2,3-d]pyrimidine en tant qu'inhibiteurs de kras g12c pour le traitement de cancer du poumon, du pancréas ou de l'intestin
MA43094A1 (fr) Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation
MA47217A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA45811A (fr) Méthodes et compositions de traitement de maladie.
MA40290A1 (fr) Agents immunorégulateurs
MA38959A1 (fr) Modulateurs du facteur b du complément
MA37829A1 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
MA43294A1 (fr) Sels et promédicaments de 1-méthyl -d-tryptophane
ATE466595T1 (de) Verbindungen und methoden für das downregulating der effekte von tgf-beta
BR112022000855A2 (pt) Moduladores de nlrp3
MA51073B1 (fr) Inhibition de l'idh-1 mutante
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
MA49396B1 (fr) Traitement de la migraine avec acétyl-leucine
MX2022005596A (es) Regimen de dosificacion para agentes anti-dll3.
BR112021010856A2 (pt) Vibegron para o tratamento de sintomas de bexiga hiperativa
EA202190678A1 (ru) Вибегрон для лечения симптомов гиперактивного мочевого пузыря